TB-500

Main evidence: Animal studies. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This pack summarizes findings on TB-500 and thymosin beta-4, alongside protocol reports, safety caveats and Australian regulatory context.

What the sources say

A 2026 scoping review mapped 80 studies and identified only one direct TB-500 study; the majority of the literature concerned thymosin beta-4 rather than the marketed fragment. (Animal studies; McGuire F et al., "Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review", 2026-06-19)
No published human trial of injected TB-500 itself is established in the cited scoping review; human reports on full-length thymosin beta-4 do not validate the fragment. (Educator material (not peer reviewed); McGuire F et al., "Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review", 2026-06-19)
Analytical research identified an N-terminally acetylated thymosin beta-4 fragment in products called TB-500; a product label alone does not establish the contents of a vial. (Educator material (not peer reviewed); Esposito S et al., "Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500", 2012-09-07)
The scoping review describes a small retrospective knee-pain report involving BPC-157 with thymosin beta-4; it was uncontrolled and does not establish benefit from injected TB-500 or combination synergy. (Small human studies; McGuire F et al., "Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review", 2026-06-19)
A first-in-human study examined IV recombinant full-length thymosin beta-4 in healthy volunteers; this is a different molecule and formulation from TB-500. (Small human studies; Wang X et al., "A first-in-human phase I study of recombinant human thymosin β4 in healthy Chinese volunteers", 2021-08-04)
Analytical research identifies an N-terminal acetylated seven-amino-acid thymosin beta-4 fragment in a product called TB-500; a product label alone cannot verify the identity or contents of a vial. (Small human studies; Esposito S et al., "Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500", 2012-09-07)
Animal and cell studies of full-length thymosin beta-4 describe wound repair, cell migration and angiogenesis, but do not demonstrate tendon, ligament, muscle or joint benefit from injected TB-500 in people. (Animal studies; McGuire F et al., "Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review", 2026-06-19)
Angiogenesis and cancer-related pathways are raised as theoretical concerns; the cited evidence does not prove that TB-500 causes cancer. Product identity, sterility, purity, immunogenicity and long-term effects remain unresolved. (Animal studies; McGuire F et al., "Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review", 2026-06-19)
The scoping review identifies no published human safety data for injected TB-500; tolerance reports for full-length thymosin beta-4 do not establish safety for the fragment or an unverified product. (Educator material (not peer reviewed); McGuire F et al., "Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review", 2026-06-19)
The TGA warns generally that unapproved peptide products may have uncertain composition and sterility and have been associated with liver damage, severe allergic reactions and inflammation; this is not a TB-500-specific incidence estimate. (Educator material (not peer reviewed); TGA and Chief Medical Officer, "Concerns regarding the public health risks associated with unapproved peptide products", 2026-06-19)
The TGA/Chief Medical Officer names TB-500 among unapproved peptide products not assessed for safety, quality or effectiveness in Australia and strongly advises against purchase or use, particularly online or from overseas. (Educator material (not peer reviewed); TGA and Chief Medical Officer, "Concerns regarding the public health risks associated with unapproved peptide products", 2026-06-19)
TGA import, supply and advertising restrictions depend on the Therapeutic Goods Act framework and applicable exemptions; this draft does not make a categorical claim about every individual possession or use situation. (Educator material (not peer reviewed); TGA and Chief Medical Officer, "Concerns regarding the public health risks associated with unapproved peptide products", 2026-06-19)
The WADA 2026 list expressly prohibits thymosin beta-4 and derivatives such as TB-500 at all times under S2 for athletes subject to the code. This anti-doping status is separate from therapeutic approval or a general criminal-law conclusion. (Educator material (not peer reviewed); WADA, 2026 Prohibited List, S2 peptide hormones and related substances, 2026-01-01)

Sources

Dosing, stacking and protocol details are not published here.